Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics innovator developing PCR-based testing solutions through its patented Co-Primers™ technology. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on developments impacting global healthcare diagnostics.
Investors and industry professionals will find curated press releases covering financial results, regulatory milestones, product launches, and strategic partnerships. Our aggregation includes updates on CODX's expanding test menu (including tuberculosis and respiratory disease diagnostics), manufacturing expansions, and progress toward decentralized testing solutions through the Co-Dx™ platform.
Key resources include earnings call transcripts, FDA clearance announcements, and analysis of emerging market initiatives like the CoSara Diagnostics joint venture in India. All content is organized chronologically demonstrate the company's trajectory while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis. Check regularly for updates on CODX's contributions to accessible, high-accuracy diagnostic testing worldwide.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, has received clearance from India's Central Drugs Standard Control Organization (CDSCO) to manufacture and sell the SARAQ™ Hepatitis C Viral Load Kit as an in vitro diagnostic. This new real-time PCR test is crucial for assessing responses to antiviral treatments for Hepatitis C, a disease causing nearly 300,000 deaths annually. With over 58 million people affected globally, the test represents an essential addition to CoSara's growing diagnostics portfolio, enhancing patient care in regions with high disease burdens.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported record full-year revenue of $97.9 million for 2021, up $23.3 million year-over-year, driven by sales of Logix Smart™ COVID-19 tests. Gross profit increased to $86.3 million, representing 88.2% of revenue. Net income was $36.7 million, down from $42.5 million in 2020. The company completed two strategic acquisitions and revealed a new at-home PCR diagnostic platform. Looking ahead, Q1 2022 revenue is projected between $21.0 million and $22.0 million.
Co-Diagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostics, will present its YourTest™ PCR device at the 3rd Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference on March 23-24, 2022, in London, England. CEO Dwight Egan will discuss the device on March 23rd at 14:00 GMT. The conference focuses on advancements in diagnostic testing for medical viruses, particularly Covid-19. Co-Diagnostics aims to enhance global access to care and innovation in diagnostics.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the enhancement of its Scientific Advisory Board (SAB) by adding renowned experts in molecular diagnostics. New members include Dr. Carl Wittwer as Chairman, along with Dr. Karen C. Carroll, Dr. Noriko Kusukawa, and Dr. Anne Wyllie. CEO Dwight Egan emphasized that their expertise will aid the company's growth and market expansion. The press release highlights the impressive qualifications of the new advisors, with many holding significant patents and research contributions in the field.
Co-Diagnostics has authorized a $30 million share repurchase program to enhance shareholder value and demonstrate confidence in its financial health. CFO Brian Brown emphasized that this decision reflects the company's strong cash flow generation and strategic capital allocation in light of current share prices. The program is flexible, allowing management to decide on the timing and method of repurchases based on market conditions and capital needs.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its earnings release date for the fourth quarter and full year 2021 on March 24, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. EDT to discuss financial results with analysts and investors. Key management on the call includes CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. The company focuses on developing molecular diagnostics technology for various applications, including infectious diseases.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its premium sponsorship of the Molecular Med Tri-Con from February 21-23, 2022, in San Diego, CA. The company will present its new Eikon PCR Platform during the event, aimed at delivering affordable, rapid, and accurate PCR testing for at-home and point-of-care use. Currently, the products based on this platform are pending FDA review and are not available for sale. This conference, organized by the Cambridge Healthtech Institute, is a key event in precision medicine and diagnostics.
Co-Diagnostics (Nasdaq: CODX) is set to showcase its advancements in molecular diagnostics at the Life Sciences Day on the Hill on February 16, 2022, in the Utah State Capital. The company has sold over 30 million COVID-19 PCR tests, marking a significant milestone two years after its first sale. CEO Dwight Egan emphasized the company's pioneering role, having received the first U.S. CE-marking for a COVID-19 test. Attendees can visit the booth from 7:00 AM to 10:00 AM to learn more about new diagnostic platforms.
Co-Diagnostics (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, received clearance from India's Central Drugs Standard Control Organization to manufacture and sell the SARAQ™ Hepatitis B (HBV) Viral Load Kit as an in vitro diagnostic. This test, utilizing patented CoPrimer™ technology, aids in monitoring antiviral treatment responses for HBV, which claims over 800,000 lives annually. CEO Dwight Egan emphasized the growing diagnostic market for endemic diseases, while CoSara Director Mohal Sarabhai noted strong demand for the test, crucial for improving patient quality of life in India.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced it will host a booth at Medlab Middle East 2022, taking place January 24-27 at the Dubai World Trade Centre. The event is a significant gathering for the global medical laboratory community, providing a platform for introducing Co-Diagnostics' products to international clients. Company representatives will showcase innovations, including a new point-of-care and at-home rapid PCR diagnostics platform. Attendees can visit Booth Z6-C26 for more information.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
